• Recently, partner company argenx reported positive clinical data for a therapy using Halozyme Therapeutics’ ENHANZE drug delivery technology, alongside an analyst reaffirming a positive rating on Halozyme.
• This combination of encouraging partner data and external analyst support underscores how Halozyme’s licensing model can be reinforced by collaborators’ clinical progress.
• We’ll now explore how argenx’s positive ENHANZE-based data could influence Halozyme Therapeutics’ broader investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme Therapeutics, you need to believe in the durability of its ENHANZE licensing model and the willingness of partners to keep building on it. The latest positive argenx data supports that case, but it does not remove the near term risk that Halozyme remains heavily reliant on a handful of partners and exposed to evolving drug pricing and reimbursement policies.

Among recent updates, the new global ENHANZE collaboration with GSK stands out as most relevant. Together with the argenx readout, it highlights how Halozyme’s growth story is closely tied to partners broadening ENHANZE use across oncology and other biologic therapies, which could meaningfully shape future royalty trajectories and the company’s ability to hit or revise its current 2026 revenue guidance of US$1.710 billion to US$1.810 billion.

Yet while partner success can be encouraging, investors should also be aware of the concentration risk if one of these key programs were to...

Halozyme Therapeutics' narrative projects $2.2 billion revenue and $1.1 billion earnings by 2029.

Uncover how Halozyme Therapeutics' forecasts yield a $85.78 fair value, a 23% upside to its current price.

Exploring Other Perspectives

While consensus focuses on steady ENHANZE growth, the most optimistic analysts see far more upside, with some assuming revenue could reach about US$2.3 billion and earnings US$1.2 billion by 2029, yet this argenx news and the ongoing partner concentration risk they highlight could still shift those expectations in either direction.

Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.